REFERENCES
- Canas CA, Tobon GJ, Arango LG, Guarin N. Developing of granulomatous thyroiditis during etanercept therapy. Clin Rheu-matol. 2009;28(Suppl 1):S17–9.
- Ohsako N, Tamai H, Sudo T, Mukuta T, Tanaka H, Kuma K, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. J Clin Endocrinol Metab. 1995;80:3653–6.
- Tomer Y, Davies TF. Infection, thyroid disease, and autoimmu-nity. Endocr Rev. 1993;14:107–20.
- Kojima M, Nakamura S, Oyama T, Sugihara S, Sakata N, Mas-awa N. Cellular composition of subacute thyroiditis. An immu-nohistochemical study of six cases. Pathol Res Pract. 2002;198: 833–7.
- Toda S, Tokuda Y, Koike N, Yonemitsu N, Watanabe K, Koike K, et al. Growth factor-expressing mast cells accumulate at thethyroid tissue-regenerative site of subacute thyroiditis. Thyroid. 2000;10:381–6.
- Chen K, Wei Y, Sharp GC, Braley-Mullen H. Decreasing TNF-alpha results in less fibrosis and earlier resolution of granulom-atous experimental autoimmune thyroiditis. J Leukoc Biol. 2007;81:306–14.
- Kaltenbach G, Lujic J, Arpin-Bott MP, Imler M. Adult onset Still disease and subacute thyroiditis. Rev Med Interne. 1996;17:427.
- Mauri S, Puig J, Martinez-Riquelme A. Painless subacute thy-roiditis with negative antithyroid antibodies during alpha inter-feron treatment in chronic hepatitis C. Med Clin (Bart). 1999;113:636.
- Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat. 2000;7:393–5.
- Candrina R, Giustina G. Iodine-induced subacute thyroiditis with thyrotoxicosis presenting as fever of unknown origin. Am J Med Sci. 1990;300:37–40.
- Vassilopoulos D, Sialevris K, Malahtari S, Deutsch M, Manolakopoulos S, Archimandritis AJ. Subacute thyroiditis pre-senting as fever of unknown origin in a patient with rheumatoid arthritis under etanercept treatment. J Clin Rheumatol. 2010;16: 88–9.
- Fang Y, Sharp GC, Braley-Mullen H. Interleukin-10 promotes resolution of granulomatous experimental autoimmune thyroid-itis. Am J Pathol. 2008;172: 1591–602.
- Fang Y, Sharp GC, Yagita H, Braley-Mullen H. A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis. J Pathol. 2008;216:505–13.
- Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301: 418–26.
- Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–57.
- Kudrin A, Chilvers ER, Ginawi A, Hazleman BL, Griffiths MH, 'Thiru S, et al. Sarcoid-like granulomatous disease following e-tanercept treatment for RA. J Rheumatol. 2007;34:648–9.
- Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005;53:618–20.
- Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol. 2008;35:349–51.
- Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. J Rheumatol. 2005;32:752–3.
- Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hop-kins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142:198–202.